Cutaneous Reactions to Targeted Therapies in Children with CNS Tumors: A Cross-Sectional Study

    February 2019 in “ Pediatric Blood & Cancer ”
    Hannah Song, Connie S. Zhong, Mark W. Kieran … Jennifer T. Huang
    Studysummary In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib Journal of cutaneous medicine and surgery · 2016
    2. Hair and Nail Adverse Events During Treatment with Targeted Therapies for Metastatic Melanoma European journal of dermatology/EJD. European journal of dermatology · 2016
    3. Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies Annals of Oncology · 2015
    4. The PRIDE Syndrome: Dermatological Side Effects of EGFR Inhibitors British Journal of Dermatology · 2006
    5. Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal Appendages Journal of Investigative Dermatology · 1984